{"id":13726,"date":"2018-01-18T11:01:59","date_gmt":"2018-01-18T11:01:59","guid":{"rendered":"https:\/\/celonpharma.com\/?p=13726"},"modified":"2022-10-19T14:47:11","modified_gmt":"2022-10-19T14:47:11","slug":"gate","status":"publish","type":"post","link":"https:\/\/celonpharma.com\/en\/gate\/","title":{"rendered":"GATE"},"content":{"rendered":"<div class=\"text-center\"><img loading=\"lazy\" decoding=\"async\" class=\"wp-image-26368 size-large aligncenter\" src=\"https:\/\/celonpharma.com\/wp-content\/uploads\/2022\/10\/1178-106-max-1024x92.png\" alt=\"\" width=\"1024\" height=\"92\" srcset=\"https:\/\/celonpharma.com\/wp-content\/uploads\/2022\/10\/1178-106-max-1024x92.png 1024w, https:\/\/celonpharma.com\/wp-content\/uploads\/2022\/10\/1178-106-max-300x27.png 300w, https:\/\/celonpharma.com\/wp-content\/uploads\/2022\/10\/1178-106-max-768x69.png 768w, https:\/\/celonpharma.com\/wp-content\/uploads\/2022\/10\/1178-106-max.png 1178w\" sizes=\"auto, (max-width: 1024px) 100vw, 1024px\" \/><\/div>\n<h2>GATE \u2013 Preclinical and clinical development of an innovative antagonist of GPR40 receptor in type 2 diabetes treatment<!--more--><\/h2>\n<p>Funding Agreement No.: POIR.01.01.01-00-0334\/17-00 under submeasure 1.1.1 PO\u00a0IR (Smart Growth Operational Programme) \u201cIndustrial research and development works carried out by enterprises\u201d.<br \/>\nDate of the contract conclusion: 08. 12. 2017<\/p>\n<p style=\"text-align: justify;\">Diabetes is a chronic, systemic metabolic disease characterised by elevated levels of glucose due to disordered secretion and activity of an endogenous hormone \u2013 insulin. Diabetes is one of the greatest and continually growing problems of modern medicine (WHO, 2016). It is estimated that an average of 4.9 million people every year die due to diabetes and its complications (50% of deaths occur in patients under the age of 60). Lack of therapy allowing for a permanent modification of the disease without developing long-term side effects presents a challenge for both research institutions and pharma companies. The project aims at designing an innovative and unique orally-administered anti-diabetic drug stimulating insulin secretion without the risk of hyperglycemia and side effects common in the other products available on the market. The drug developed by Celon Pharma will specifically activate a signal pathway operating mainly in pancreas beta cells which has never been done before in diabetes treatment. The GPR40 receptor will be activated in beta cells only in the presence of high glucose concentrations and therefore it will stimulate insulin secretion during and directly after the meal. Furthermore, this newly synthesised chemical substance is a much stronger antagonist than natural GPR40 ligands, i.e. fatty acids, and its unique micromolecular nature diminish toxicity characteristic of fatty acids. Therefore, this new drug will be a strong competitor for those already on the market and will offer an alternative to patients. The project will be carried out in four stages and its result will be the final dosage form (tablets or capsules) tested in phase 2 clinical trial to confirm its effectiveness and safety for patients.<\/p>\n<p style=\"text-align: justify;\"><strong><br \/>\nTotal value of the GATE project:<\/strong>39\u00a0328\u00a0955,23 PLN<br \/>\n<strong>Total value of funding:<\/strong>24\u00a0783 853,02 PLN<\/p>\n","protected":false},"excerpt":{"rendered":"<p>GATE \u2013 Preclinical and clinical development of an innovative antagonist of GPR40 receptor in type 2 diabetes treatment<\/p>\n","protected":false},"author":11,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[98],"tags":[],"class_list":["post-13726","post","type-post","status-publish","format-standard","hentry","category-ue-co-financed-projects-implemented"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.0 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>GATE - Celon Pharma<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/celonpharma.com\/en\/gate\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"GATE - Celon Pharma\" \/>\n<meta property=\"og:description\" content=\"GATE \u2013 Preclinical and clinical development of an innovative antagonist of GPR40 receptor in type 2 diabetes treatment\" \/>\n<meta property=\"og:url\" content=\"https:\/\/celonpharma.com\/en\/gate\/\" \/>\n<meta property=\"og:site_name\" content=\"Celon Pharma\" \/>\n<meta property=\"article:published_time\" content=\"2018-01-18T11:01:59+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2022-10-19T14:47:11+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/celonpharma.com\/wp-content\/uploads\/2022\/10\/1178-106-max-1024x92.png\" \/>\n<meta name=\"author\" content=\"S\u0142awomir Ni\u017cnik\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"S\u0142awomir Ni\u017cnik\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/gate\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/gate\\\/\"},\"author\":{\"name\":\"S\u0142awomir Ni\u017cnik\",\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/#\\\/schema\\\/person\\\/44c54386ed112173d6e8bcbeb6425338\"},\"headline\":\"GATE\",\"datePublished\":\"2018-01-18T11:01:59+00:00\",\"dateModified\":\"2022-10-19T14:47:11+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/gate\\\/\"},\"wordCount\":324,\"image\":{\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/gate\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/celonpharma.com\\\/wp-content\\\/uploads\\\/2022\\\/10\\\/1178-106-max-1024x92.png\",\"articleSection\":[\"UE - co-financed projects implemented\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/gate\\\/\",\"url\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/gate\\\/\",\"name\":\"GATE - Celon Pharma\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/gate\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/gate\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/celonpharma.com\\\/wp-content\\\/uploads\\\/2022\\\/10\\\/1178-106-max-1024x92.png\",\"datePublished\":\"2018-01-18T11:01:59+00:00\",\"dateModified\":\"2022-10-19T14:47:11+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/#\\\/schema\\\/person\\\/44c54386ed112173d6e8bcbeb6425338\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/gate\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/celonpharma.com\\\/en\\\/gate\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/gate\\\/#primaryimage\",\"url\":\"https:\\\/\\\/celonpharma.com\\\/wp-content\\\/uploads\\\/2022\\\/10\\\/1178-106-max-1024x92.png\",\"contentUrl\":\"https:\\\/\\\/celonpharma.com\\\/wp-content\\\/uploads\\\/2022\\\/10\\\/1178-106-max-1024x92.png\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/gate\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"GATE\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/\",\"name\":\"Celon Pharma\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/#\\\/schema\\\/person\\\/44c54386ed112173d6e8bcbeb6425338\",\"name\":\"S\u0142awomir Ni\u017cnik\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"GATE - Celon Pharma","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/celonpharma.com\/en\/gate\/","og_locale":"en_US","og_type":"article","og_title":"GATE - Celon Pharma","og_description":"GATE \u2013 Preclinical and clinical development of an innovative antagonist of GPR40 receptor in type 2 diabetes treatment","og_url":"https:\/\/celonpharma.com\/en\/gate\/","og_site_name":"Celon Pharma","article_published_time":"2018-01-18T11:01:59+00:00","article_modified_time":"2022-10-19T14:47:11+00:00","og_image":[{"url":"https:\/\/celonpharma.com\/wp-content\/uploads\/2022\/10\/1178-106-max-1024x92.png","type":"","width":"","height":""}],"author":"S\u0142awomir Ni\u017cnik","twitter_card":"summary_large_image","twitter_misc":{"Written by":"S\u0142awomir Ni\u017cnik","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/celonpharma.com\/en\/gate\/#article","isPartOf":{"@id":"https:\/\/celonpharma.com\/en\/gate\/"},"author":{"name":"S\u0142awomir Ni\u017cnik","@id":"https:\/\/celonpharma.com\/en\/#\/schema\/person\/44c54386ed112173d6e8bcbeb6425338"},"headline":"GATE","datePublished":"2018-01-18T11:01:59+00:00","dateModified":"2022-10-19T14:47:11+00:00","mainEntityOfPage":{"@id":"https:\/\/celonpharma.com\/en\/gate\/"},"wordCount":324,"image":{"@id":"https:\/\/celonpharma.com\/en\/gate\/#primaryimage"},"thumbnailUrl":"https:\/\/celonpharma.com\/wp-content\/uploads\/2022\/10\/1178-106-max-1024x92.png","articleSection":["UE - co-financed projects implemented"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/celonpharma.com\/en\/gate\/","url":"https:\/\/celonpharma.com\/en\/gate\/","name":"GATE - Celon Pharma","isPartOf":{"@id":"https:\/\/celonpharma.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/celonpharma.com\/en\/gate\/#primaryimage"},"image":{"@id":"https:\/\/celonpharma.com\/en\/gate\/#primaryimage"},"thumbnailUrl":"https:\/\/celonpharma.com\/wp-content\/uploads\/2022\/10\/1178-106-max-1024x92.png","datePublished":"2018-01-18T11:01:59+00:00","dateModified":"2022-10-19T14:47:11+00:00","author":{"@id":"https:\/\/celonpharma.com\/en\/#\/schema\/person\/44c54386ed112173d6e8bcbeb6425338"},"breadcrumb":{"@id":"https:\/\/celonpharma.com\/en\/gate\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/celonpharma.com\/en\/gate\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/celonpharma.com\/en\/gate\/#primaryimage","url":"https:\/\/celonpharma.com\/wp-content\/uploads\/2022\/10\/1178-106-max-1024x92.png","contentUrl":"https:\/\/celonpharma.com\/wp-content\/uploads\/2022\/10\/1178-106-max-1024x92.png"},{"@type":"BreadcrumbList","@id":"https:\/\/celonpharma.com\/en\/gate\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/celonpharma.com\/en\/"},{"@type":"ListItem","position":2,"name":"GATE"}]},{"@type":"WebSite","@id":"https:\/\/celonpharma.com\/en\/#website","url":"https:\/\/celonpharma.com\/en\/","name":"Celon Pharma","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/celonpharma.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/celonpharma.com\/en\/#\/schema\/person\/44c54386ed112173d6e8bcbeb6425338","name":"S\u0142awomir Ni\u017cnik"}]}},"_links":{"self":[{"href":"https:\/\/celonpharma.com\/en\/wp-json\/wp\/v2\/posts\/13726","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/celonpharma.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/celonpharma.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/celonpharma.com\/en\/wp-json\/wp\/v2\/users\/11"}],"replies":[{"embeddable":true,"href":"https:\/\/celonpharma.com\/en\/wp-json\/wp\/v2\/comments?post=13726"}],"version-history":[{"count":2,"href":"https:\/\/celonpharma.com\/en\/wp-json\/wp\/v2\/posts\/13726\/revisions"}],"predecessor-version":[{"id":26426,"href":"https:\/\/celonpharma.com\/en\/wp-json\/wp\/v2\/posts\/13726\/revisions\/26426"}],"wp:attachment":[{"href":"https:\/\/celonpharma.com\/en\/wp-json\/wp\/v2\/media?parent=13726"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/celonpharma.com\/en\/wp-json\/wp\/v2\/categories?post=13726"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/celonpharma.com\/en\/wp-json\/wp\/v2\/tags?post=13726"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}